Dyadic International DYAI
NASDAQ DYAI
$0.51 0.00 (-0.31%)
As of: Sep 10, 2026 · 1:27 PM EDT

Dyadic International (DYAI) Share-based Compensation (2018 - 2026)

Dyadic International's (DYAI) quarterly Share-based Compensation came in at $5.6 million in Q1 2026, down 10.61% year-over-year from $6.3 million in Q1 2025, and up 2829.94% quarter-over-quarter from $192339.0 in Q4 2025.

Analysis

Dyadic International (DYAI) Share-based Compensation (2018 - 2026) Analysis & Trends

Dyadic International has disclosed Share-based Compensation across 9 years of filings, most recently posting $5.6 million for Q1 2026.

  • In Q1 2026, Share-based Compensation fell 10.61% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $5.6 million (down 10.61% YoY), while the FY2025 annual figure was $5.4 million, down 7.36% from the prior year.
  • Share-based Compensation came in at $5.6 million for Q1 2026 at Dyadic International, up from $192339.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.3 million in Q1 2025 to a low of $192339.0 in Q4 2025.
  • Average Share-based Compensation over 5 years is $4.4 million, with a median of $5.5 million recorded in 2023.
  • The largest YoY upside for Share-based Compensation was 14.6% in 2022 against a maximum downside of 98.71% in 2022.
  • Over 5 years, Share-based Compensation stood at $480734.0 in 2022, then tumbled by 38.04% to $297859.0 in 2023, then slipped by 7.74% to $274808.0 in 2024, then slumped by 30.01% to $192339.0 in 2025, then soared by 2829.94% to $5.6 million in 2026.
  • Per Business Quant data, the three most recent Share-based Compensation figures were $5.6 million in Q1 2026, $192339.0 in Q4 2025, and $5.9 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Amgen 206.38 Bn 192.39 Bn 7.24 Bn 247.00 Mn
2 Gilead Sciences 180.22 Bn 177.04 Bn 6.22 Bn 231.00 Mn
3 Vertex Pharmaceuticals 131.28 Bn 123.42 Bn 2.84 Bn 108.10 Mn
4 Regeneron Pharmaceuticals 81.96 Bn 73.97 Bn 3.93 Bn 243.00 Mn
5 Argenx Se 60.49 Bn 55.30 Bn 1.37 Bn -
6 Moderna 53.90 Bn 48.76 Bn 52.00 Mn 120.00 Mn
7 Alnylam Pharmaceuticals 33.41 Bn 30.11 Bn 992.69 Mn 86.63 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn 77.40 Mn
9 Roivant Sciences 29.08 Bn 29.08 Bn 1.16 Mn 83.34 Mn
10 Dyadic International 18.44 Mn 10.48 Mn - 5.64 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 5.64 Mn
Dec 31, 2025 192,339.00
Sep 30, 2025 5.93 Mn
Jun 30, 2025 6.00 Mn
Mar 31, 2025 6.30 Mn
Dec 31, 2024 274,808.00
Sep 30, 2024 5.85 Mn
Jun 30, 2024 5.83 Mn
Mar 31, 2024 5.91 Mn
Dec 31, 2023 297,859.00
Sep 30, 2023 5.50 Mn
Jun 30, 2023 5.46 Mn
Mar 31, 2023 5.42 Mn
Dec 31, 2022 480,734.00
Sep 30, 2022 5.28 Mn
Jun 30, 2022 5.50 Mn
Mar 31, 2022 5.43 Mn
Dec 31, 2021 459,702.00
Sep 30, 2021 4.82 Mn
Jun 30, 2021 4.80 Mn